Point-of-care testing of methamphetamine and cocaine utilizing wearable sensors

Anal Biochem. 2024 Apr 13:115526. doi: 10.1016/j.ab.2024.115526. Online ahead of print.ABSTRACTThe imperative for the point-of-care testing of methamphetamine and cocaine in drug abuse prevention necessitates innovative solutions. To address this need, we have introduced a multi-channel wearable sensor harnessing CRISPR/Cas12a system. A CRISPR/Cas12a based system, integrated with aptamers specific to methamphetamine and cocaine, has been engineered. These aptamers function as signal-mediated intermediaries, converting methamphetamine and cocaine into nucleic acid signals, subsequently generating single-stranded DNA to activate the Cas12 protein. Additionally, we have integrated a microfluidic system and magnetic separation technology into the CRISPR system, enabling rapid and precise detection of cocaine and methamphetamine. The proposed sensing platform demonstrated exceptional sensitivity, achieving a detection limit as low as 0.1 ng/mL. This sensor is expected to be used for on-site drug detection in the future.PMID:38621604 | DOI:10.1016/j.ab.2024.115526
Source: Analytical Biochemistry - Category: Biochemistry Authors: Source Type: research